Janux Therapeutics (JANX) Return on Sales (2021 - 2025)
Janux Therapeutics (JANX) has disclosed Return on Sales for 5 consecutive years, with 11.36% as the latest value for Q4 2025.
- On a quarterly basis, Return on Sales fell 485.0% to 11.36% in Q4 2025 year-over-year; TTM through Dec 2025 was 11.36%, a 485.0% decrease, with the full-year FY2025 number at 11.36%, down 485.0% from a year prior.
- Return on Sales was 11.36% for Q4 2025 at Janux Therapeutics, down from 2.43% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.67% in Q2 2024 to a low of 240.64% in Q2 2025.
- A 5-year average of 22.35% and a median of 8.38% in 2022 define the central range for Return on Sales.
- Biggest YoY gain for Return on Sales was 6148bps in 2025; the steepest drop was -23997bps in 2025.
- Janux Therapeutics' Return on Sales stood at 8.3% in 2021, then surged by 32bps to 5.65% in 2022, then increased by 15bps to 4.78% in 2023, then crashed by -36bps to 6.52% in 2024, then crashed by -74bps to 11.36% in 2025.
- Per Business Quant, the three most recent readings for JANX's Return on Sales are 11.36% (Q4 2025), 2.43% (Q3 2025), and 240.64% (Q2 2025).